BioSante Pharmaceuticals, Inc. of Lincolnshire, IL has been honored with a recognition by R&D Directions in its selection of "100 Great Investigational Drugs."

LINCOLNSHIRE, Ill., Aug. 31, 2011 /PRNewswire-USNewswire/ -- Announcing a special recognition appearing in the March, 2011 issue of R&D Directions published by Engel Publishing Partners. BioSante Pharmaceuticals, Inc. was selected for the following honor:

(Photo: [ http://photos.prnewswire.com/prnh/20110831/DC60637 ])

"100 Great Investigational Drugs"

A spokesperson from BioSante Pharmaceuticals, Inc. commented on the recognition: "This is quite an honor for us. The fact that R&D Directions included BioSante Pharmaceuticals, Inc. in its selection of "100 Great Investigational Drugs," signals that our constant efforts towards business excellence are paying off. We are proud to be included in this recognition."

About BioSante Pharmaceuticals, Inc.:a short profile by and about the honoree:

BioSante (NASDAQ: [ BPAX ]) is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead product and the product recognized as being among the top 100 Great Investigational Drugs of 2011 is LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD), specifically hypoactive sexual desire disorder (HSDD). LibiGel is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment (SPA) and is the only product in the world in Phase III clinical development for HSDD for which there is no FDA-approved product for this significant unmet medical need in the U.S. A new drug application (NDA) is planned for the end of 2012. Additional information is available online at: [ www.biosantepharma.com ].

Following the publication of BioSante Pharmaceuticals, Inc.'s selection for R&D Directions'100 Great Investigational Drugs list, American Registry seconded the honor and added BioSante Pharmaceuticals, Inc. to the "Registry of Business Excellence™". An exclusive recognition plaque, [ shown here ], has been designed to commemorate this honor.

For more information on BioSante Pharmaceuticals, Inc., located in Lincolnshire, IL please visit [ www.biosantepharma.com ].

This press release was written by American Registry, LLC with contributions from BioSante Pharmaceuticals, Inc. on behalf of BioSante Pharmaceuticals, Inc. and was distributed by PR Newswire, a subsidiary of United Business Media.

American Registry, LLC, recognizes excellence in top businesses and professionals. The Registry™ includes over 2 million significant business and professional recognitions, including all those included in R&D Directions'100 Great Investigational Drugs list. For more information, search The Registry at [ http://www.americanregistry.com ].

SOURCE BioSante Pharmaceuticals, Inc.

[ Back to top ]

Contributing Sources

Market Wire

N@N

BioSante Pharmaceuticals, Inc. Selected For "100 Great Investigational Drugs"

BioSante Pharmaceuticals, Inc. Selected For "100 Great Investigational Drugs"